Thomas Jefferson University Taps Perthera for Multi-omic Molecular Diagnostic Analyses

Perthera to perform comprehensive molecular profiling and analysis
services for Thomas Jefferson University Hospitals’ cancer patients

MCLEAN, Va.–(BUSINESS WIRE)–Perthera,
a premier personalized medicine service company, and Thomas
Jefferson University today announced a collaboration that will
provide Perthera’s advanced, multi-omic, molecularly targeted
diagnostics and related bioinformatics services and analysis to cancer
patients at Thomas Jefferson University Hospitals facilities and
affiliates.

Through the collaboration, Thomas Jefferson University Hospitals’
oncologists will have the opportunity to evaluate Perthera’s services,
which will provide them with a molecular analysis of their patients’
tumors as well as outcomes data, with the long-term goals of not only
demonstrating the success of personalized medicine but also enhancing
treatment procedures against the disease.

“Perthera will be a strong addition to Jefferson’s formidable and
growing efforts to provide patients with personalized and evidence-based
care, and will allow our oncologists to more completely and simply
understand the nature and progression of any patient’s unique cancer,”
said Rebecca O’Shea, senior vice president clinical services of Thomas
Jefferson University Hospitals. “We’ve been eager to launch this
relationship for some time, and anticipate it making a real difference
in our patients’ lives.”

Perthera is the only organization to combine the latest molecular
profiling, including genomic, proteomic and phosphoproteomic analysis,
with a patient’s medical history and state-of-the-art diagnostic
technology, thereby enabling oncologists to deliver precision medicine
to treat an individual patient’s unique cancer.

“Our relationship with Thomas Jefferson University [Hospitals] is an
exciting one, as the organization’s leadership truly values personalized
medicine and the advances it has made to revolutionize the standard of
cancer treatment for all patients,” said Andrew
Mignatti, president and CEO of Perthera. “Together we’re introducing
a new era of personalized cancer therapy by empowering patients and
their oncologists with better knowledge than ever existed before about
what is happening within the molecular structure of their cancer cells.”

Through the company’s PrecisOn process, Perthera will provide Thomas
Jefferson University Hospitals’ oncologists with a comprehensive
understanding of the molecular architecture of their patients’ tumors.
The multiple molecular analyses of each tumor will be integrated into
Perthera’s Expert Oncologist system (also known as ExpO), an expert
learning database that sources the most current clinical knowledge and
research/drug information available, to facilitate analysis of
multi-omic molecular profiles in context with the patient’s medical
history.

Once testing is complete, Perthera’s Medical Review Panel — which is
comprised of disease-specific cancer experts — will analyze and
interpret the profiling data to provide actionable therapies and
clinical trial options to oncologists and their patients in the final
Perthera report. Perthera will then correlate molecular stratification
for therapies with patient outcomes, thus providing a unique registry to
validate molecular profiling-based therapies.

About Perthera

Perthera, based in McLean, Va., is the premier personalized medicine
service company. As the only organization to combine the latest
multi-omic molecular profiling, including genomic, proteomic and
phosphoproteomic analysis, with a patient’s medical history and
state-of-the-art diagnostic technology, Perthera enables oncologists to
deliver precision medicine to treat an individual patient’s unique
cancer.

For more information, visit us on www.perthera.com,
Twitter,
Facebook
and YouTube.

Contacts

Focused Image for Perthera
Shannon Joyce, 703-342-8784
sjoyce@focusedimage.com